Home> Products> Inhibitors> KX2-391 dihydrochloride-CAS 1038395-65-1
price inquiry for CAS:1038395-65-1, Product:KX2-391 dihydrochloride

KX2-391 dihydrochloride CAS: 1038395-65-1

Category: Inhibitors
Product Name: KX2-391 dihydrochloride
Cat No: I000226
CAS No: 1038395-65-1
Synonyms: N-benzyl-2-[5-[4-(2-morpholin-4-ylethoxy)phenyl]pyridin-2-yl]acetamide;dihydrochloride
Molecular Formula: C26H31Cl2N3O3
Molecular Weight: 504.45
Solubility: 10 mM in DMSO
Target: Src
IC50: 9-60 nM (GI50) [1]
Storage: Store at -20°C
CAS 1038395-65-1,KX2-391 dihydrochloride
  • Description

KX2-391 2Hcl (KX01) is the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.
IC50 value: 9-60 nM (GI50) [1]
Target: Src kinase
in vitro: KX2-391 is a Src inhibitor that is directed to the Src substrate pocket. KX2-391 shows steep dose-response curves against Huh7 (GI 50 = 9 nM), PLC/PRF/5 (GI 50 = 13 nM), Hep3B (GI 50 = 26 nM), and HepG2 (GI 50 = 60 nM), four hepatic cell cancer (HCC) cell lines[1]. KX2-391 is found to inhibit certain leukemia cells that are resistant to current commercially available drugs, such as those derived from chronic leukemia cells with the T3151 mutation. KX2-391 is evaluated in engineered Src driven cell growth assays inNIH3T3/c-Src527F and SYF/c-Src527F cells and exhibits GI50 with 23 nM and 39 nM, respectively [2].
in vivo: In pre-clinical animal models of cancer, orally administered KX2-391 is shown to inhibit primary tumor growth and to suppress metastasis [2].

  • References

[1]. Lau GM, et al. Expression of Src and FAK in hepatocellular carcinoma and the effect of Src inhibitors on hepatocellular carcinoma in vitro. Dig Dis Sci, 2009, 54(7), 1465-1474.
[2]. Fallah-Tafti A, et al. Thiazolyl N-benzyl-substituted acetamide derivatives: synthesis, Src kinase inhibitory and anticancer activities. Eur J Med Chem, 2011, 46(10), 4853-4858.

price inquiry for CAS:1038395-65-1, Product:KX2-391 dihydrochloride